{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:43:29Z","timestamp":1791477809078,"version":"4.3.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psilocybin therapy has demonstrated efficacy for cancer-related anxiety and depression, but resource-intensive individual treatment models raise important questions for psychedelic public health about equitable access and scalability. In our prior Phase 1\/2 study of group retreat psilocybin therapy for patients with metastatic cancer, we observed partial responders who did not achieve full therapeutic benefit. No published research has examined whether partial responders might benefit from a second psilocybin therapy experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-arm Phase 1 study to assess the safety of a second experience of Group Retreat Psilocybin Therapy for partial responders from our prior study. Protocol modifications addressed dose as a potential contributor to partial response: the initial dose was increased to 35 mg, and an optional 10 mg booster could be requested by participants who reported low subjective effect at 60\u201390 min and passed a safety check. Pre-retreat antidepressant tapering was not required. The intervention was delivered in a group retreat format with four primary facilitators and included three preparation sessions, a single psilocybin dosing day, and four integration sessions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirteen participants (mean age 56 years, 70% female, 38% on concurrent antidepressants) completed the intervention. No serious adverse events occurred; mild adverse events included transient hypertension (\n                      <jats:italic>n<\/jats:italic>\n                      = 4), nausea (\n                      <jats:italic>n<\/jats:italic>\n                      = 3), and headache (\n                      <jats:italic>n<\/jats:italic>\n                      = 1). Seven participants (54%) received the booster dose. Mean Hospital Anxiety and Depression Scale (HADS) Total scores decreased from 15.08 (SD 4.35) at baseline to 9.00 (SD 4.62) at Day +8, with improvements maintained through 24-week follow-up (mean 10.42, SD 6.93); 69% achieved HADS scores below the clinical threshold. The proportion of participants with a \u201ccomplete\u201d mystical experience (Mystical Experience Questionnaire \u2265 60%) increased from 38% in the first experience to 77% in the second, without an increase in challenging experiences (Challenging Experiences Questionnaire). Social support, social identification, and group cohesion scores showed progressive improvements that persisted at 24 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>A second experience of group retreat psilocybin therapy was safe and feasible for partial responders with metastatic cancer. The protocol modifications\u2014higher dose, optional booster, and no antidepressant tapering requirement\u2014did not introduce new safety concerns and were associated with substantially enhanced mystical experiences and preliminary efficacy signals. These findings support further investigation of retreatment protocols for partial responders and contribute to developing scalable group-based models relevant to psychedelic public health, where the resource intensity of individual treatment remains a fundamental barrier to population-level access.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1810904","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:17:55Z","timestamp":1776176275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience"],"prefix":"10.3389","volume":"14","author":[{"given":"Anthony L.","family":"Back","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine","place":["Seattle, WA, United States"]},{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie A.","family":"McGregor","sequence":"additional","affiliation":[{"name":"Orion Center for Integrative Medicine","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie L.","family":"Thorn","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalin","family":"Harvey","sequence":"additional","affiliation":[{"name":"Quantified Citizen","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna","family":"Blom","sequence":"additional","affiliation":[{"name":"Harmony Retreats","place":["Union, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Callan","sequence":"additional","affiliation":[{"name":"Private Practice","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Guy","sequence":"additional","affiliation":[{"name":"Private Practice","place":["Seattle, WA, United States"]},{"name":"Seattle Mindfulness Center","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameet","family":"Kumar","sequence":"additional","affiliation":[{"name":"Miami Veterans Affairs Healthcare System","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Hershberg","sequence":"additional","affiliation":[{"name":"Independent Researcher","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Layer","sequence":"additional","affiliation":[{"name":"Harmony Retreats","place":["Union, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Levin","sequence":"additional","affiliation":[{"name":"Harmony Retreats","place":["Union, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Myers","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Perez","sequence":"additional","affiliation":[{"name":"Harmony Retreats","place":["Union, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Salmonson","sequence":"additional","affiliation":[{"name":"Harmony Retreats","place":["Union, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Thompson","sequence":"additional","affiliation":[{"name":"Private Practice","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Whinney","sequence":"additional","affiliation":[{"name":"Independent Researcher","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1293243","DOI":"10.3389\/fpsyt.2023.1293243","article-title":"Group psychedelic therapy: empirical estimates of cost-savings and improved access","volume":"14","author":"Marseille","year":"2023","journal-title":"Front Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1556\/2054.2019.015","article-title":"The psychedelic renaissance and the limitations of a White-dominant medical framework: a call for indigenous and ethnic minority inclusion","volume":"4","author":"George","year":"2019","journal-title":"J Psychedelic Stud."},{"key":"B3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.genhosppsych.2025.07.020","article-title":"A dose of therapy with psilocybin - a meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy","volume":"96","author":"Hultgren","year":"2025","journal-title":"Gen Hosp Psychiatry."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jad.2018.09.027","article-title":"Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression","volume":"243","author":"Rosenblat","year":"2019","journal-title":"J Affect Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3109\/09540261.2013.842542","article-title":"Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review","volume":"26","author":"Grassi","year":"2014","journal-title":"Int Rev Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1025726","DOI":"10.3389\/fpsyt.2022.1025726","article-title":"The economics of psychedelic-assisted therapies: a research agenda","volume":"13","author":"Marseille","year":"2022","journal-title":"Front Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/02791072.2019.1593559","article-title":"Psychedelic-assisted group therapy: a systematic review","volume":"51","author":"Trope","year":"2019","journal-title":"J Psychoactive Drugs."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/28314425251413856.","article-title":"Group retreat psilocybin therapy for people with metastatic cancer with anxiety and depression: safety and efficacy outcomes of a phase 1\/2 study","author":"Back","year":"2026","journal-title":"Psychedelic Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/28314425251404460.","article-title":"Group retreat psilocybin therapy for people with metastatic cancer with anxiety and depression: a rite of passage facilitation model for a phase 1\/2 study","author":"Back","year":"2026","journal-title":"Psychedelic Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1176\/appi.ajp.20221043","article-title":"Must psilocybin always \u201cAssist Psychotherapy\u201d?","volume":"181","author":"Goodwin","year":"2024","journal-title":"Am J Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"14914","DOI":"10.1038\/s41598-019-50612-3","article-title":"Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat","volume":"9","author":"Smigielski","year":"2019","journal-title":"Sci Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/cncr.30012","article-title":"Refinement and revalidation of the demoralization scale: the DS-II-external validity","volume":"122","author":"Robinson","year":"2016","journal-title":"Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/cncr.30015","article-title":"Refinement and revalidation of the demoralization scale: the DS-II-internal validity","volume":"122","author":"Robinson","year":"2016","journal-title":"Cancer."},{"key":"B17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jpainsymman.2014.04.012","article-title":"Initial validation of the death and dying distress scale for the assessment of death anxiety in patients with advanced cancer","volume":"49","author":"Krause","year":"2015","journal-title":"J Pain Symptom Manage."},{"key":"B18","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/13548506.2010.487107","article-title":"Development and validation of a self-report for the assessment of adjustment disorders","volume":"15","author":"Einsle","year":"2010","journal-title":"Psychol Health Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0207820","DOI":"10.1371\/journal.pone.0207820","article-title":"The national institutes of health measure of healing experience of all life stressors (NIH-HEALS): factor analysis and validation","volume":"13","author":"Ameli","year":"2018","journal-title":"PLoS ONE."},{"key":"B20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/bjso.12006","article-title":"A single-item measure of social identification: reliability, validity, and utility","volume":"52","author":"Postmes","year":"2013","journal-title":"Br J Soc Psychol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00008483-200311000-00001","article-title":"A short social support measure for patients recovering from myocardial infarction: the ENRICHD social support inventory","volume":"23","author":"Mitchell","year":"2003","journal-title":"J Cardiopulm Rehabil."},{"key":"B23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1037\/0022-3514.69.4.719","article-title":"The structure of psychological well-being revisited","volume":"69","author":"Ryff","year":"1995","journal-title":"J Pers Soc Psychol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","article-title":"Assessing the clinical significance of change scores recorded on subjective outcome measures","volume":"27","author":"Hurst","year":"2004","journal-title":"J Manipulative Physiol Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J Psychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J Psychopharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"623985","DOI":"10.3389\/fphar.2021.623985","article-title":"Psychedelic communitas: intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness","volume":"12","author":"Kettner","year":"2021","journal-title":"Front Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41591-025-03685-9","article-title":"An international delphi consensus for reporting of setting in psychedelic clinical trials","volume":"31","author":"Pronovost-Morgan","year":"2025","journal-title":"Nat Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1097\/HCR.0000000000000379","article-title":"Establishing the minimal clinically important difference for the hospital anxiety and depression scale in patients with cardiovascular disease","volume":"39","author":"Lemay","year":"2019","journal-title":"J Cardiopulm Rehabil Prev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"20451253251381074","DOI":"10.31234\/osf.io\/caup9_v2","article-title":"Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design","volume":"15","author":"Muthumaraswamy","year":"2025","journal-title":"Ther Adv Psychopharmacol."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1810904\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:17:56Z","timestamp":1776176276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1810904\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":31,"alternative-id":["10.3389\/fpubh.2026.1810904"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1810904","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1810904"}}